CA
NZ
UK
AU
IND
US
…
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Replimune Group is a clinical-stage biotechnology company developing engineered oncolytic viruses intended to kill cancer cells and stimulate anti-tumor immune responses, with lead programs such as RP1 in clinical development. Long-term growth drivers include positive clinical trial outcomes, supportive combination data with checkpoint inhibitors, and progress in manufacturing and regulatory pathways that may support future commercialization.
Key risks include clinical and regulatory setbacks, high cash burn with potential dilution, manufacturing scale-up challenges and intense competition in oncology.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | -174.00M | -118.04M | -80.87M | -52.62M | -30.83M |
| Net income | -174.28M | -117.65M | -83.27M | -54.53M | -30.83M |
| Selling general administrative | 50.55M | 38.77M | 23.20M | 17.44M | 8.77M |
| Reconciled depreciation | 2.45M | 2.15M | 1.71M | 0.53M | 0.15M |
| Ebit | -177.08M | -118.31M | -79.95M | -56.20M | -22.97M |
| Ebitda | -177.40M | -114.06M | -76.10M | -52.60M | -22.82M |
| Depreciation and amortization | -0.32M | 4.26M | 3.85M | 3.60M | 0.15M |
| Non operating income net other | - | - | -0.10M | 4.31M | 0.11M |
| Operating income | -177.08M | -118.31M | -79.95M | -56.20M | -30.95M |
| Other operating expenses | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M |
| Interest expense | 4.16M | 2.22M | 3.06M | 1.92M | 0.00M |
| Tax provision | 0.29M | - | - | - | - |
| Interest income | - | - | - | 0.51M | 2.58M |
| Net interest income | -4.16M | -2.22M | -3.06M | -1.92M | 2.58M |
| Income tax expense | 0.29M | -0.39M | 2.40M | 1.90M | 0.11M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M |
| Total other income expense net | 3.08M | 0.28M | -0.92M | 3.57M | -5.00M |
| Net income from continuing ops | -174.28M | -118.04M | -80.87M | -52.62M | -30.83M |
| Net income applicable to common shares | - | -118.04M | -80.87M | -52.62M | -30.83M |
| Breakdown | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Total assets | 487.72M | 646.59M | 461.19M | 543.10M | 234.10M |
| Other current assets | 8.08M | 6.28M | 5.27M | 7.45M | 5.70M |
| Total liab | 113.21M | 91.30M | 49.96M | 44.37M | 50.38M |
| Total stockholder equity | 374.51M | 555.29M | 411.23M | 498.73M | 183.72M |
| Other current liab | 3.33M | 24.70M | 13.39M | 0.51M | 0.30M |
| Common stock | 0.06M | 0.06M | 0.05M | 0.05M | 0.04M |
| Capital stock | 0.06M | 0.06M | 0.05M | 0.05M | 0.04M |
| Retained earnings | -701.28M | -485.49M | -311.20M | -193.17M | -112.30M |
| Other assets | - | - | 1.64M | 1.64M | 1.64M |
| Cash | 74.46M | 146.59M | 105.95M | 182.52M | 59.50M |
| Total current liabilities | 40.44M | 33.83M | 20.76M | 14.55M | 11.87M |
| Current deferred revenue | 30.65M | - | - | 8.22M | 4.85M |
| Net debt | 1.41M | -85.83M | -73.11M | -149.24M | -17.71M |
| Short term debt | 3.88M | 3.76M | 3.63M | 3.46M | 3.28M |
| Short long term debt total | 75.87M | 60.76M | 32.84M | 33.28M | 41.79M |
| Other stockholder equity | 1070.87M | 1034.99M | 723.36M | 692.24M | 62.86M |
| Property plant equipment | - | - | 55.58M | 7.44M | 58.21M |
| Total current assets | 433.67M | 592.60M | 403.98M | 483.75M | 174.25M |
| Net tangible assets | - | - | 411.23M | 498.73M | 183.72M |
| Short term investments | 346.21M | 436.80M | 289.71M | 293.78M | 109.06M |
| Net receivables | 4.92M | 2.94M | 3.06M | 2.95M | 2.96M |
| Long term debt | 44.81M | 28.65M | - | - | 9.80M |
| Inventory | - | - | - | -2.95M | -2.96M |
| Accounts payable | 2.58M | 5.36M | 3.73M | 2.35M | 3.43M |
| Accumulated other comprehensive income | 4.86M | 5.73M | -0.97M | -0.39M | -0.98M |
| Common stock total equity | - | - | - | 0.05M | 0.04M |
| Retained earnings total equity | - | - | - | -193.17M | -112.30M |
| Non currrent assets other | 1.70M | 1.64M | 1.64M | 1.64M | 1.64M |
| Non current assets total | 54.05M | 53.99M | 57.22M | 59.35M | 59.85M |
| Capital lease obligations | 31.06M | 32.11M | 32.84M | 33.28M | 31.99M |
| Long term debt total | - | - | - | - | 34.77M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -142.50M | 0.53M | -186.38M | 1.31M | -63.34M |
| Change to liabilities | - | 1.12M | 2.38M | -1.34M | -0.17M |
| Total cashflows from investing activities | - | -1.81M | -188.78M | -5.23M | -65.94M |
| Net borrowings | - | -0.26M | -10.79M | 10.00M | 9.94M |
| Total cash from financing activities | 311.30M | 6.60M | 372.46M | 100.17M | 101.39M |
| Change to operating activities | - | 6.12M | 4.54M | -11.59M | -1.37M |
| Net income | -174.28M | -118.04M | -80.87M | -52.62M | -30.83M |
| Change in cash | 40.64M | -76.57M | 123.02M | 34.25M | 9.23M |
| Begin period cash flow | 107.58M | 184.15M | 61.14M | 26.89M | 17.66M |
| End period cash flow | 148.23M | 107.58M | 184.15M | 61.14M | 26.89M |
| Total cash from operating activities | -128.05M | -82.18M | -61.39M | -60.55M | -25.38M |
| Issuance of capital stock | 187.29M | 0.00M | 286.11M | 61.88M | 103.34M |
| Depreciation | 2.45M | 2.15M | 1.71M | 0.53M | 0.15M |
| Other cashflows from investing activities | - | - | - | 1.31M | -63.34M |
| Dividends paid | - | - | 91.65M | 28.14M | - |
| Change to account receivables | - | - | 0.33M | - | - |
| Sale purchase of stock | 92.78M | - | 91.65M | 28.14M | 101.39M |
| Other cashflows from financing activities | 31.60M | 6.86M | 96.50M | 38.34M | -1.95M |
| Change to netincome | - | 26.47M | 12.88M | 7.90M | 8.28M |
| Capital expenditures | 2.27M | 2.34M | 2.39M | 6.54M | 2.60M |
| Cash flows other operating | - | - | 2.50M | -15.02M | -2.79M |
| Cash and cash equivalents changes | - | - | 122.30M | 34.38M | 10.07M |
| Change in working capital | 15.12M | 7.24M | 3.51M | -15.41M | -1.25M |
| Stock based compensation | 28.13M | 24.25M | 11.79M | 7.74M | 2.73M |
| Other non cash items | 0.53M | 2.22M | 0.18M | 0.16M | 0.09M |
| Free cash flow | -130.32M | -84.52M | -63.78M | -67.09M | -27.98M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group Inc |
1.33 8.28% |
17.39 | - | - | - | 1.04 | -0.24 |
| NVO Novo Nordisk A/S |
0.85 2.22% |
39.14 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
10.31 1.95% |
540.00 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.50 0.68% |
818.77 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Philip Astley-Sparke FSA | CEO & Director | 1971 |
| Dr. Robert Coffin Ph.D. | Founder, Pres, Chief R&D Officer and Director | 1965 |
| Ms. Tanya N. Lewis M.S. | Chief Devel. Operations Officer | 1971 |
| Mr. Sushil Patel Ph.D. | Chief Commercial Officer | 1971 |
| Ms. Jean M. Franchi | Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer | 1966 |
| Dr. Colin A. Love Ph.D. | Chief Operating Officer | 1958 |
| Dr. Pamela Esposito Ph.D. | Chief Bus. Officer | 1975 |
| Mr. Philip Astley-Sparke F.S.A. | Executive Chairman | 1971 |
| Dr. Sushil Patel Ph.D. | Chief Executive Officer | 1971 |
| Dr. Robert Coffin Ph.D. | Founder, Chief Scientist & Director | 1965 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.52%
Communication Services
+0.32%
Consumer Cyclical
+1.01%
Consumer Defensive
+0.00%
Energy
+0.01%
Financial Services
+0.62%
Financials
-2.62%
Healthcare
+0.51%
Industrials
+0.71%
Real Estate
+0.72%
Technology
-0.46%
Utilities
+0.54%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...